Validation of Combs prognostic scoring system in Indian recurrent glioma patients treated with re-radiation

IF 1.8 Q3 ONCOLOGY

Radiation Oncology Journal Pub Date : 2024-01-23 DOI:10.3857/roj.2023.00542

Debnarayan Dutta, Meenu Jose, S. Kalavagunta, A. Sasidharan, Haridas Nair, A. Edappattu

{"title":"Validation of Combs prognostic scoring system in Indian recurrent glioma patients treated with re-radiation","authors":"Debnarayan Dutta, Meenu Jose, S. Kalavagunta, A. Sasidharan, Haridas Nair, A. Edappattu","doi":"10.3857/roj.2023.00542","DOIUrl":null,"url":null,"abstract":"Hypo-RT, and UF-RT cohort was 18.8 months (range, 2.4 to 76.8); 6.6 months (range, 2 to 17.4), and 13.9 months (range, 3 to 131.9). Median OS as per Combs criteria were 16.6 months (Group a), 24.6 months (Group b), 4.6 months (Group c), and 3 months (Group d). Significant survival benefit was with good KPS score (KPS >80 vs. <80; 20.46 vs. 5.25 months; p < 0.001), patients receiving salvage chemotherapy (20.46 vs. 6.96 months; p = 0.001), and patients received re-RT biological equivalent dose (BED 3 ) >80 Gy (16.62 vs. 5.48 months; p = 0.03). Median overall survival (OS) in our patient cohort and Combs cohort in Group a was 16.6 and 19.5 months; Group b was 24.6 and 11.3 months; Group c was 4.7 and 8.1 months, and Group d was 2 and 5.5 months, respectively. Six months survival in our patient cohort and Combs cohort in Groups a, b, c, d were 100%, 92%, 34%, 17% and 94%, 79%, 70%, 41%, respectively. Twelve months survival in our patient cohort and Combs cohort in Groups a, b, c, d were 88%, 74%, 22%, 0% and 88%, 47%, 22%, 7%, respectively. Conclusion: Modified Combs prognostic factors predicts OS and is applicable in Indian subcontinent patient population.","PeriodicalId":46572,"journal":{"name":"Radiation Oncology Journal","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiation Oncology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3857/roj.2023.00542","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Hypo-RT, and UF-RT cohort was 18.8 months (range, 2.4 to 76.8); 6.6 months (range, 2 to 17.4), and 13.9 months (range, 3 to 131.9). Median OS as per Combs criteria were 16.6 months (Group a), 24.6 months (Group b), 4.6 months (Group c), and 3 months (Group d). Significant survival benefit was with good KPS score (KPS >80 vs. <80; 20.46 vs. 5.25 months; p < 0.001), patients receiving salvage chemotherapy (20.46 vs. 6.96 months; p = 0.001), and patients received re-RT biological equivalent dose (BED 3 ) >80 Gy (16.62 vs. 5.48 months; p = 0.03). Median overall survival (OS) in our patient cohort and Combs cohort in Group a was 16.6 and 19.5 months; Group b was 24.6 and 11.3 months; Group c was 4.7 and 8.1 months, and Group d was 2 and 5.5 months, respectively. Six months survival in our patient cohort and Combs cohort in Groups a, b, c, d were 100%, 92%, 34%, 17% and 94%, 79%, 70%, 41%, respectively. Twelve months survival in our patient cohort and Combs cohort in Groups a, b, c, d were 88%, 74%, 22%, 0% and 88%, 47%, 22%, 7%, respectively. Conclusion: Modified Combs prognostic factors predicts OS and is applicable in Indian subcontinent patient population.

查看原文本刊更多论文

在接受再放射治疗的印度复发性胶质瘤患者中验证康布斯预后评分系统

低RT组和UF-RT组的中位OS分别为18.8个月（2.4至76.8个月）、6.6个月（2至17.4个月）和13.9个月（3至131.9个月）。根据康布斯标准，中位生存期分别为16.6个月（a组）、24.6个月（b组）、4.6个月（c组）和3个月（d组）。KPS评分良好者（KPS>80 vs. 80 Gy，16.62 个月 vs. 5.48 个月；P = 0.03）生存期显著延长。在我们的患者队列和 Combs 队列中，a 组的中位总生存期（OS）分别为 16.6 个月和 19.5 个月；b 组为 24.6 个月和 11.3 个月；c 组为 4.7 个月和 8.1 个月；d 组为 2 个月和 5.5 个月。在我们的患者队列和康博斯队列中，a、b、c、d 组的 6 个月存活率分别为 100%、92%、34%、17% 和 94%、79%、70%、41%。我们的患者队列和康博斯队列中 a、b、c、d 组的 12 个月存活率分别为 88%、74%、22%、0% 和 88%、47%、22%、7%。结论修改后的康布斯预后因素可预测 OS，适用于印度次大陆患者群体。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Radiation Oncology Journal ONCOLOGY-

CiteScore

3.50

自引率

4.30%

发文量